2024-03-27 16:00Financial Performance - The company reported a net loss for the year 2023, continuing its trend of not achieving profitability since its listing[4]. - The company reported a revenue of ¥357,083,325.91 in 2023, a decrease of 65.49% compared to ¥1,034,595,413.49 in 2022[22]. - The net loss attributable to shareholders was ¥1,482,732,319.40, an increase of 63.04% from a loss of ¥909,431,138.03 in the previous year[26]. - The basic earnings per share for 2023 was -¥6.01, compared to -¥3.68 in 2022, indicating a significant decline[24]. - Total assets decreased by 18.75% to ¥9,318,769,372.66 from ¥11,468,958,286.71 in 2022[26]. - The net assets attributable to shareholders decreased by 21.84% to ¥5,274,604,094.18 from ¥6,748,089,902.12 in 2022[26]. - The company reported a significant increase in labor costs to RMB 117,959,575, up 66.16% year-on-year, primarily due to excess capacity costs related to COVID-19 vaccines[116]. - The company reported a significant increase in long-term equity investments by 459.02% to RMB 18,168,286.75[132]. Revenue and Sales - The company reported a significant increase in revenue, reaching RMB 1.5 billion, representing a 25% year-over-year growth[20]. - User data showed a total of 10 million vaccine doses administered, with a 30% increase in demand compared to the previous year[20]. - The company achieved sales revenue of approximately RMB 561.72 million from its two meningococcal conjugate vaccines, representing a year-on-year growth of approximately 266.39%[39]. - Sales revenue from the meningococcal vaccine reached RMB 561,724,018.29, a significant increase of 266.39% year-over-year[143]. - Sales revenue from the COVID-19 vaccine was RMB 36,656,258.24, a decline of 96.86% compared to the previous year[108]. - The company recognized a revenue reduction of RMB 253,198,186.62 due to actual and expected returns of COVID-19 vaccine products[108]. Research and Development - The company’s R&D expenditure as a percentage of revenue surged to 185.30%, up by 108.95 percentage points from 76.35% in 2022[24]. - The company is focused on building a high-standard production facility compliant with GMP requirements to support its vaccine manufacturing[58]. - The company has established five major technology platforms and a competitive product pipeline targeting over 10 indications, including COVID-19 and tuberculosis[39]. - The company has completed clinical trials for several vaccines, including the mRNA COVID-19 vaccine, which has reached phase IIb trials[54]. - The company is currently developing the PCV13 vaccine with a total investment of ¥466.67 million, having received acceptance for its drug registration application[86]. - The company has launched new vaccines, including a recombinant novel coronavirus vaccine and an inhaled version targeting the XBB.1.5 variant, with patent protection lasting until 2040[141]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[20]. - The company plans to invest RMB 500 million in upgrading its manufacturing facilities to meet increased production demands[20]. - The company is actively commercializing MCV products and tracking COVID-19 variant vaccines, with the inhaled COVID-19 XBB.1.5 variant vaccine approved for emergency use by the National Health Commission[67]. - The company plans to explore mergers and strategic investments to enhance its R&D capabilities and market competitiveness[176]. - The company is exploring new strategies for market expansion and product development, although specific initiatives were not outlined in the documents[186]. Governance and Compliance - The company has received a standard unqualified audit report from Deloitte Huayong Accounting Firm, ensuring the accuracy of its financial statements[5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[5]. - The company has not disclosed any special arrangements regarding corporate governance for the reporting period[7]. - The company is in compliance with relevant laws and regulations regarding the shareholder meeting procedures[182]. - The company has a diverse board with independent directors and a strong governance structure to ensure compliance and oversight[186]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% driven by new product launches and market expansion[20]. - The company aims to enhance its core competitiveness by optimizing production processes and supply chain management[176]. - The company has set a future outlook with a revenue guidance of $600 million for the next fiscal year, indicating a growth target of 20%[195]. - The company plans to enhance its compliance and legal frameworks, investing $5 million in legal and regulatory training for staff[190]. - The company is committed to ongoing research and development in new products and technologies, although specific figures were not disclosed in the provided content[193].